Brokers Set Expectations for ATXS FY2025 Earnings

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Astria Therapeutics in a note issued to investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the biotechnology company will earn ($1.98) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share.

ATXS has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday, March 11th. JMP Securities started coverage on Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Finally, Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $30.00.

Astria Therapeutics Stock Performance

ATXS opened at $5.16 on Thursday. Astria Therapeutics has a 1-year low of $3.56 and a 1-year high of $12.92. The company has a market cap of $291.20 million, a price-to-earnings ratio of -2.47 and a beta of 0.68. The company’s fifty day moving average price is $5.42 and its two-hundred day moving average price is $7.95.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently made changes to their positions in the business. KLP Kapitalforvaltning AS purchased a new stake in Astria Therapeutics during the fourth quarter worth about $41,000. Tower Research Capital LLC TRC increased its stake in shares of Astria Therapeutics by 109.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 2,766 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $50,000. Virtus ETF Advisers LLC bought a new stake in shares of Astria Therapeutics in the 4th quarter worth approximately $65,000. Finally, GAMMA Investing LLC lifted its stake in Astria Therapeutics by 1,127.4% in the first quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,971 shares during the last quarter. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.